Basic Science

SC01 Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory MS Individuals of Different Disability Levels, poster
SC02 Brain Structural And Functional Abnormalities in Multiple Sclerosis, poster
SC03 A Comparison of XP23896 With DMF, the Active Ingredient of BG-12, poster
SC04 The Critical Role of the Toll Like Receptor 2/ Myeloid Differentiation Primary Response Gene (88) Pathway in Danger Signaling and Failure of Myelin Regeneration, poster
SC05 How Are Relapses, Symptoms and Disease Progression Linked in Early Multiple Sclerosis?, poster
SC06 Migraine is Comorbid with Multiple Sclerosis in Nationwide Inpatient Sample, poster
SC07 Characterizing Benign Multiple Sclerosis Using Age, Disease Duration and Disability Status in a Large Longitudinal Database, poster
SC08 Costimulatory Molecule CD40 is Elevated in Patients with MS, poster

Cognition, Depression, and Psychosocial

CG01 Social Workers Collaborate to Improve Care for Veterans with MS, poster
CG02 The MS Social Workers Collaborative of Washington: Sustainable and Thriving at Year 3!, poster
CG03 Can Demyelinative Lesion in the Brain Cause Behavioral Change? poster
CG04 Self-Efficacy Improvement in Multiple Sclerosis (SIMS): A Pilot Study, poster
CG05 An Update on Physical Activity and Cognition in Persons with MS, poster
CG06 Optical Coherence Tomography Metrics and Third Ventricular Width are Associated with Cortical Atrophy in Persons with Multiple Sclerosis, poster
CG07 Prism: A Novel Research Tool to Determine Prevalence of Pseudobulbar Affect Among People with MS, poster
CG08 A Mother’s Love, Multiple Sclerosis & the Correlation Between Flare Incidences, poster
CG09 Multiple Sclerosis Presenting as a Focal Cognitive Syndrome, poster
CG10 Characteristics of Depression Disorders in Multiple Sclerosis, poster
CG11 A Study to Identify the Psychosocial Needs of Caregivers of Persons with MS, poster
CG12 The Soul Therapy, poster
CG13 Computer Practice and Cognitive Functioning in Multiple Sclerosis, poster
CG14 Cognitive Dysfunction in MS: Education Translates Science Into Practice, poster
CG15 Subtypes of Depression in Multiple Sclerosis: Phase 1 - Best Evidence Synthesis and Epidemiological Prognosis Framework, poster
CG16 Addressing the Challenges Faced by Family Caregivers of People with MS, poster
CG17 Effectiveness of a Psychosocial Educational Wellness Program in Multiple Sclerosis, poster
CG18 Health-Related Quality of Life Among People with MS and Urinary Symptoms, poster
CG19 Productivity Impairment Among People with MS and Urinary Symptoms, poster
CG20 The Relationship Between Pain and Depression in MS, poster
CG21 Cognitive Reserve as a Possible Predictor of Cognitive Impairment in People with MS, poster
CG22 Nursing and Social Work Collaboration: Pioneering Patient Centered Care for
2012 CMSC Posters

Written by Rachelle Ramirez - Last Updated Thursday, 17 December 2015 16:49

CG24 Negative Feelings Due Multiple Sclerosis in Caregivers and Patients
CG25 Quality of Life in Caregivers of Elderly Patients with MS
CG26 The ‘Long Duration’ Multiple Sclerosis Patient: No One Gets Away That Easy
CG27 A Pilot Interdisciplinary Group Cognitive Rehab Intervention for MS: 1-Year Follow-Up
CG28 The Effect of a Creative Art Program on Individuals with Multiple Sclerosis, poster
CG29 MS Depression Screening: Influence on Provider Interventions and Clinical Outcomes
CG30 InMotion: A Phone-Based RCT to Increase Physical Activity and Improve Mood, poster
CG31 Normative Data for the Stroop Color Word Test for a North American Population
CG32 Motor and Neurocognitive Functioning in a Sample of Veterans with Multiple Sclerosis
CG33 The Addition of Biofeedback and Mindfulness Based Training Components to a

Disease Management, Mechanisms, and Treatment

DX01 Benefit/Risk Evaluation of Multiple Sclerosis Treatments by Patients and Physicians
DX02 Changes in Disability Status in Beta-Interferon Treated Multiple Sclerosis Patients
DX03 What Prompts a Switch in Disease Modifying Therapy Beyond First Line Therapies
DX04 Hospitalizations Among Patients with Multiple Sclerosis
DX05 Challenging Management of Neuromyelitis Optica During Pregnancy
DX06 Clinical Outcomes and Cause of Death in Patients From the 21-Year Long-Term Study
DX07 Interactive Multiple Sclerosis Self-Paced Nurse Education Program
DX08 Fingolimod Efficacy by Prior Disease-Modifying Therapy Experience: FREEDOMS
DX09 Patient Preferences for Multiple Sclerosis Treatments: TRIBUNE Study
DX10 Interferon Beta-1A Titration Reduces Subjective Flu-Like Symptoms and Fever
DX11 Subcutaneous Interferon Beta-1A Treatment of Pediatric Multiple Sclerosis
DX12 The Multiple Sclerosis Self-Management Workshop
DX13 Rituximab Therapy in Secondary-Progressive Multiple Sclerosis: A Two-Year Analysis of First Dose Observation Data for MS Treatment with Fingolimod
DX14 The History of the Vascular Theories of Multiple Sclerosis
DX15 Clinical Aspects of Multiple Sclerosis Patients with Normal Spinal Cord Imaging
DX16 Incidence of Silent Spinal Cord Lesions in Relapsing Remitting Multiple Sclerosis
DX17 T-Cell Subtype in Multiple Sclerosis Patients Treated with Fingolimod
DX18 The Food Critic Who Couldn’t Taste and 6 Other Cases of Dysgeusia in Multiple Sclerosis
DX19 Pseudobulbar Affect in MS: Baseline Interrelations in a Study Cohort
DX21 Association of Neurologic Deficits: Manual Injection vs. Autoinjector Use
DX22 Patient Injection Setting Preferences on an Autoinjector for IFN ß-1A, poster
DX23 As Observational Study Examining Factors Affecting Quality of Life in Subjects Daclizumab HYP Improves Quality of Life in Multiple Sclerosis Patients
DX24 Fingolimod Slows Brain Volum Loss Regardless of Inflammatory Activity
DX25 Identifying the Needs of Women With Relapsing Remitting MS of Childbearing Age
DX26 Multiple Sclerosis and Huntington's Chorea: a Case Report and Literature Review
DX27 Safety and Tolerability of BG-12 in the Phase 3 CONFIRM Study
DX28 Strive Study: Natalizumab Anti-JCV Seronegative Patients With Early MS
DX29 Quantifying Neurodegeneration in Multiple Sclerosis White Matter Tracts With...
DX34  Cost Sharing and Initiation Disease-Modifying-Therapy for MS,
DX35  You Are What You Walk: Investigating the Clinical Meaningfulness of the Timed 25 Foot Walk (T25FW),
DX36  Neuromyelitis Optica (NMO) Diagnosed As Syrinx On MRI,
DX37  Establishing a Gilenya Service in Greater Manchester (UK),
DX38  Observations of Patients With Multiple Sclerosis Reporting Endovascular Procedures,
DX39  Alemtuzumab Improves Quality of Life Compared To IFNB-1A in CARE-MS I,
DX40  Alemtuzumab-Associated Infusion Reactions in CARE-MS I,
DX41  Observations On the Design of Secondary Progressive MS Trials,
DX42  Utilization of Shared Medical Appointment for First Day Observation for Fingolimod,
DX43  A Novel Method of Sharing Practice Patterns: the Mellen Center “Approach”
DX44  Fingolimod Efficacy by Time Since First Symptoms in Phase 3 Studies,
DX45  Patient-Reported Outcomes After Switching To Fingolimod: EPOC Study Design,
DX46  How To Improve Patient-Centered Care With Increased Cost Effectiveness,
DX47  Atypical Multiple Sclerosis With Bilateral Internal Jugular Vein Occlusion,
DX48  Multiple Sclerosis After Bariatric Surgery,
DX49  Hospital and ER Use Among Newly Diagnosed Multiple Sclerosis Patients,
DX50  Multiple Sclerosis Patient Treated With Natalizumab Develops Immune Thrombocytopenic Purpura,
DX51  The Gulf War Era Multiple Sclerosis Cohort: Clinical Features At First Diagnosis,
DX52  Rebound Symptoms in Clinically Isolated Syndrome (CIS) Or Multiple Sclerosis
DX53  NARCOMS: Simple Observation of Relapses Perceived To Be Inferior To Therapy,
DX54  Vitamin D Status in African-American Patients With Multiple Sclerosis: a Cohort Study,
DX55  Cost Effectiveness of Early Versus Delayed Treatment With Fingolimod,
DX56  High Dose Immunosuppressive Therapy (HDIT) With Autologous Hematopoietic Stem Cell Transplantation (HSCT) In Multiple Sclerosis,
DX57  A One-Year Analysis of Fingolimod Utilization Patterns in Multiple Sclerosis,
DX58  Pegylated Interferon Beta-1a in Relapsing MS: Baseline Characteristics,
DX59  Phase 2 Study of Fingolimod Efficacy and Safety in Japanese Patients,
DX60  Correlation Between QoL and Clinical and MRI Measures in Early MS,
DX61  Physical and Mental Comorbidities in a Managed Care Population With Multiple Sclerosis,
DX62  Impact of Comorbidities On Medical Costs in Health Plan Members With Multiple Sclerosis,
DX63  Daclizumab HYP Reduces Multiple Sclerosis Clinical Disease Activity,
DX64  Adrenocorticotropic Hormone Treatment of Multiple Sclerosis Exacerbations,
DX65  Clinical Importance of Accelerometer Output in Multiple Sclerosis,
DX66  Consistent Efficacy of Fingolimod Across Clinical Development Program,
DX67  Pregnancy, Alphafetoprotein and MS,
DX68  Predictors of Medication Adherence To Fingolimod: An Analysis of Specialty Pharmacy Data,
DX69  Anti-JCV Antibody Status in MS Patients: Baseline Results of STRATIFY-2,
DX70  Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy,
DX71  Final Results From the Intramuscular Interferon Beta-1A Pregnancy Registry,
DX72  Safety and Pharmacokinetics of BG-12 Given With and Without Aspirin,
DX73  CCSVI: the Message in Social Media,
DX74  Does Risk Tolerance To MS Therapies Change Over Time? a NARCOMS Survey,
DX75  Effects of BG-12 On Quality of Life in Relapsing-Remitting MS in DEFINE,
DX76  The Modified Rankin Score Compared To EDSS and MRI Measures in the CCSVI Registry,
DX77  Sustained Long Term Use of Interferon Beta-1A in Patients With Relapsing MS,
DX80  Longitudinal Follow Up of a Cohort of Subjects With Incidental Abnormal MRI
DX81  Total Macular Volume and its Association With Ambulatory Parameters in Patients With Cognitive Impairment
DX82  The Pacific Northwest MS Registry: Year 4 Update and Diagnosis Validation
DX83  Comparing Rituximab Induction Followed by Glatiramer Acetate To Glatiramer Acetate Alone in Patients With Cognitive Impairment Maintain Good Treatment Adherence With Clinical and Demographic Features of Participants in a VA Longitudinal Study

Rehabilitation
RH01  Mentally Simulated Motor Actions in Neurorehabilitation: A New Protocol for Enhancing Upper Limb Function
RH02  Effects of a Physical Therapy Reference for Neurologists Treating Multiple Sclerosis
RH03  Physical Therapy, A Part of a Multidisciplinary Team for People with Multiple Sclerosis
RH04  Comparison of Actigraph Accelerometers in Persons with MS and Healthy Controls
RH05  Two Conditions of Administering the Six-Minute Walk in Persons with MS
RH06  Effects of a Fall Prevention Initiative on Falls During Outpatient Visits in an MS Clinic
RH07  The Effects of a 6-Minute Endurance Walk on Selected Gait Characteristics
RH08  Newly Diagnosed Clinic: Emerging Model in MS Care
RH09  Activity-Based Rehabilitation May Preserve Function in Multiple Sclerosis
RH10  Impact of a Hip Flexion Assist Device on Gait Performance in MS
RH11  Agreement Between Self-Report and Clinician-Administered EDSS Scores
RH12  Validity and Sensitivity of Spatiotemporal Parameters of Gait in MS
RH13  People with Multiple Sclerosis Show Improved Gait with Balance-Based Therapy: Berg Balance Scale Scores in Persons with Multiple Sclerosis are Different in Fatigued vs. Non-Fatigued Conditions
RH14  Validation of Self-Reported Balance and Mobility Measures in Multiple Sclerosis
RH15  Validation of an Abbreviated Activities-Specific Balance Confidence Scale in Multiple Sclerosis
RH16  Walking Impairment and Gait Variability in Multiple Sclerosis
RH17  Whole Limb Vibration Facilitates Magnetic Evoked Potential (MEP) Responses
RH18  Targeted Lower Extremity Joint Training Effects on Gait Abnormalities
RH19  Evaluation of a Multiple Sclerosis Educational Track for Physical Therapy Students
RH20  The Multiple Sclerosis Educational Track for Physical Therapy Students: Measurement of Upper Limb Function and the Expanded Disability Status Scale
RH21  Quality of Life
RH22  Qualitative Needs Assessment of People with Multiple Sclerosis
RH23  Employment Needs of People with Multiple Sclerosis
RH24  Psychometric Properties of Three Depression Scales in People with Multiple Sclerosis
RH26  The Multiple Sclerosis Self-Management Scale: Psychometric Testing
RH27  Weight Status and Disability in Multiple Sclerosis
RH28  Multiple Sclerosis Walking Scale-12 Scores and Gait Parameters
RH29  Neurotronics Walkaide in MS Patients
RH30  Predicting Community Participation in Adults with Multiple Sclerosis
RH31  Dual Task Mobility and Falls Risk in Persons with Multiple Sclerosis
RH32  The Path to Work in People with Multiple Sclerosis
RH33  Tracking Instrumented Gait and Balance in Multiple Sclerosis Over 18 Months
RH34  The Effects of Strength Training Protocols on Fatigue, Strength and Quality of Life in Persons with MS
RH35  Physical Activity, Self-Efficacy, and Health-Related Quality of Life In Persons with MS
RH36  A Comparison of Balance Training in Multiple Sclerosis: Conventional Training vs. Nintendo® Wii Fit™ Game Play
2012 CMSC Posters

Written by Rachelle Ramirez - Last Updated Thursday, 17 December 2015 16:49

RH37 Living Well with Multiple Sclerosis: A Healthcare Provider Perspective,
RH38 Validation of the Six Spot Step Test as a Measure of Ambulation in Multiple Sclerosis

Symptom Management

SX01 Dose-Finding Study of Dextromethorphan/Quinidine for Central Neuropathic Pain
SX02 Evaluation of Provider Referrals to Additional Services for Management of Multiple Sclerosis
SX03 Assessing Quality Measures in Multiple Sclerosis Patients with Initiation of Dalfampridine and Mobility in Multiple Sclerosis: Beyond the Timed 25-Foot Walk Test
SX04 Fatigue: Take Control: A VA Multi-Center Randomized Controlled Trial,
SX05 Walking Speed and Health-Related Quality of Life in Multiple Sclerosis,
SX06 Correlation of Functional Impact of Headaches in an MS Cohort,
SX07 Disease Modifying Treatments and Multiple Sclerosis Symptoms,
SX08 Office-Based Single-Bolus Intrathecal Baclofen Trials in MS Patients: A Call to Action
SX10 Gilenya® Risk and Support Program (GRASP): A Melbourne Experience
SX11 Participation in Multiple Sclerosis Wellness Programs and Services,
SX12 Features in Spontaneous Speech and Conversational Narrative: Comparison of Persons with MS and Those with AD
SX13 There's More Hidden Below the Belt Than First Thought,
SX14 Treatment Consensus for Flu Like Symptoms During Interferon Therapy for Multiple Sclerosis
SX15 Ampyra Improves Walking Speed and Community Participation in Veterans with Multiple Sclerosis
SX16 Demographic Assessment of Dalfampridine Extended Release Tablets Usage
SX17 Patient or Caregiver Knowledge of Dalfampridine Safety and Use Information
SX18 Prescriber Utilization Study of Dalfampridine Extended Release Tablets
SX19 The Impact of Tobacco Use on Symptoms in Persons with Multiple Sclerosis
SX20 Town Hall Discussions: Information, Support, Growth and Development of Multiple Sclerosis Nurses During Moderated Dialogues
SX21 Prevalence of Asymptomatic Urinary Tract Infections in Persons with Multiple Sclerosis
SX22 Neuromyelitis Optica is Frequently Associated with Severe and Intractable Pain
SX23 Multiple Sclerosis and Spinal Cord Care: Expanding Access and Coordination of Care
SX24 Symptomatic Correlates of Six-Minute Walk Performance in Persons with Multiple Sclerosis: Reports from a Multiethnic Cohort
SX25 Migraines in Multiple Sclerosis

Start of page